Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab + Nab-Paclitaxel for UTUC
NCT07126119Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in upper tract urothelial carcinoma (UTUC), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Pathological Complete Response. Started Jul 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07126119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126119.